Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


MDS and Anemia

MDS and Anemia
Dr. Janis Abkowitz, President Elect of the American Society of Hematology (ASH), is from Seattle Cancer Care Alliance. She tells about her study of hemoglobin in myelodysplastic syndromes (MDS) resulting in anemia. It has lead to better outcomes for patients with MDS because they are rethinking how the anemia develops and how it should be treated. Listen to her assessment of progress being made in the treatment of MDS.

Related Videos

Transplant for MDS Patients

In this interview from the 2011 American Society of Hematology (ASH) Annual Meeting, Dr. Bart Scott talks with Patient Power about Myelodysplastic Syndrome (MDS). He describes the disease and symptoms, including fatigue, shortness of breath, bruising, and increased infections. He also describes the demographic most commonly effected by the condition--Caucasian men, approximately 72 years old. For patients requiring red cell transfusions, several treatments have been FDA approved. Dr. Scott discusses Revlmid, or Lenalidomide, Vidaza, also known as Azacitidine and Decitabine, or Dacogen. Learn how the type of MDS determines the treatment received.